| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 20060 |
| Drug | Atezolizumab in combination with bevacizumab |
| Brand | Tecentriq® |
| Indication | For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 21/12/2020 |
| Rapid review completed | 08/02/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab in combination with bevacizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 24/02/2021 |
| Pre-submission consultation with Applicant | 22/11/2021 |
| Full submission received from Applicant | 26/07/2022 |
| Preliminary review sent to Applicant | 24/11/2022 |
| NCPE assessment re-commenced | 22/12/2022 |
| Factual accuracy sent to Applicant | 08/03/2023 |
| NCPE assessment re-commenced | 15/03/2023 |
| NCPE assessment completed | 08/05/2023 |
| NCPE assessment outcome | The NCPE recommends that atezolizumab (Tecentriq ®) in combination with bevacizumab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. March 2024
